N/A
Manufactured by ANI Pharmaceuticals, Inc.
26,851 FDA adverse event reports analyzed
Last updated: 2026-04-14
HYDROXYZINE HYDROCHLORIDE ORAL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for HYDROXYZINE HYDROCHLORIDE ORAL include PRURITUS, DRUG INEFFECTIVE, FATIGUE, NAUSEA, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for HYDROXYZINE HYDROCHLORIDE ORAL.
Out of 11,638 classified reports for HYDROXYZINE HYDROCHLORIDE ORAL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 26,851 FDA FAERS reports that mention HYDROXYZINE HYDROCHLORIDE ORAL. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PRURITUS, DRUG INEFFECTIVE, FATIGUE, NAUSEA, RASH, PRODUCT DOSE OMISSION ISSUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with HYDROXYZINE HYDROCHLORIDE ORAL. Always verify the specific product and NDC with your pharmacist.